Form 4: Terns Pharmaceuticals Executive Melita Sun Jung Reports Stock Option Grant

Melita Sun Jung, Chief Business Officer of Terns Pharmaceuticals, reports the acquisition of stock options for 475,000 shares.

Summary

• Melita Sun Jung, Chief Business Officer of Terns Pharmaceuticals, filed a Form 4 on May 2, 2024.
• The report details the grant of stock options to purchase 475,000 shares of Terns Pharmaceuticals common stock.
• The exercise price of the stock options is $5.08 per share.
• The options were granted on May 1, 2024, and expire on April 30, 2034.
• The options vest over four years, with 25% vesting on the first anniversary of May 1, 2024, and the remainder vesting monthly thereafter.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.

Future Outlook

NA

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, used to attract and retain talent and align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded pharmaceutical companies.
• The size of the grant is likely determined by a number of factors including the executive's role, experience, and company performance.
• Comparable companies in the biotech sector, such as Madrigal Pharmaceuticals or Viking Therapeutics, also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates